Sunday , July 22 2018
Home / HIV/AIDS / Sanofi and NIH Researchers Develop Three-in-One Antibodies to Treat HIV

Sanofi and NIH Researchers Develop Three-in-One Antibodies to Treat HIV

CAMBRIDGE, Mass., Sept. 20, 2017 /PRNewswire/ — In a landmark study published in the journal Science today, researchers produced genetically engineered antibodies with the highest activity and breadth of coverage yet seen against human immunodeficiency virus (HIV-1).

Natural antibodies recognize a single target on a foreign protein. In this study, antibodies were engineered to recognize three different target sites in one molecule. These HIV “trispecific” antibodies were highly effective in suppressing virus growth and infection.

“Unlike natural antibodies, trispecific antibodies engage multiple targets in a single product. This approach to multi-targeting provides an opportunity to improve protection against HIV and represents a foundation for potential new treatments of cancer, immune, and infectious diseases,” said Gary Nabel, Chief Scientific Officer and Senior Vice President of Sanofi, and lead co-author of the paper in Science.

A key challenge in using broadly neutralizing HIV antibodies to tackle the ongoing HIV pandemic is overcoming the remarkable genetic diversity of viruses around the world.

The trispecific antibodies showed better coverage than any previously-studied antibody, neutralizing 99% of more than 200 diverse strains of HIV-1. One of the trispecific antibodies that recognized the CD4 binding site, the membrane proximal external region (MPER), and the V1V2 glycan site of HIV fully protected monkeys against infection from a mixture of two simian/human immunodeficiency viruses (SHIV). These viruses had shown resistance to single-target antibodies.

The trispecific antibody builds on proprietary technology developed by Sanofi, and was identified after dozens of different bispecific and trispecific combinations were tested. Sanofi is now manufacturing this trispecific antibody for use in a Phase I clinical trial expected to begin in 2018 at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

“Combination therapy has already demonstrated its value in HIV and cancer therapy. Trispecific antibodies represent a potential new class of therapeutics that can block multiple targets with a single agent. This new approach supports a central pillar of Sanofi’s strategy to use multi-targeting to develop transformative medicines for incurable diseases,” said Dr. Nabel.

Today’s published results come from the work of Sanofi, NIAID, Harvard Medical School, The Scripps Research Institute, and the Ragon Institute of MGH, MIT and Harvard.

“At Sanofi, we understand that no single company can conquer major public health threats on its own. By joining forces, the public and private sectors can accelerate our efforts and likelihood of success against infectious diseases and cancer,” said Elias Zerhouni, M.D., President, Global R&D, Sanofi. “We are committed to working collaboratively to develop innovative health solutions.”

The trispecific antibodies are currently in preclinical development, and their safety and efficacy have not been fully evaluated by any regulatory authority.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Check Also

FDA Approves Janssen’s Symtuza, the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

TITUSVILLE, N.J., July 17, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the …